The CAPACITY-COVID Collaborative Consortium and LEOSS Study Group examined outcomes of hospitalized COVID-19 patients, both with and without pre-existing heart disease. The CAPACITY-COVID (NCT04325412) registry was launched in March 2020 and has collected data from adults hospitalized for COVID-19 from … Continue Reading about Greater risk of death in heart failure patients hospitalized for COVID-19
Main Content
Latest Videos
Frontiers in Cardiology
Top Highlights of ACC 2022
The American College of Cardiology (ACC) 2022 Scientific Session was a hybrid event which took place from April 2 to 4, 2022, in Washington, … Continue Reading about Top Highlights of ACC 2022
Cardiovascular sequelae in COVID-19 survivors
Cardiovascular (CV) events associated with acute COVID-19 infection include myocardial infarction (MI), arrhythmias, multisystem … Continue Reading about Cardiovascular sequelae in COVID-19 survivors
Current trends
Greater risk of death in heart failure patients hospitalized for COVID-19
The CAPACITY-COVID Collaborative Consortium and LEOSS Study Group examined outcomes of hospitalized COVID-19 patients, both with and without pre-existing heart disease. The CAPACITY-COVID (NCT04325412) … Continue Reading about Greater risk of death in heart failure patients hospitalized for COVID-19
Empagliflozin and Renal Outcomes in Heart Failure
The EMPEROR-Reduced (NCT03057977) and EMPEROR-Preserved (NCT03057951) trials demonstrated that empagliflozin could reduce the risk of hospitalization for heart failure (HF) both in patients with HF and reduced left … Continue Reading about Empagliflozin and Renal Outcomes in Heart Failure
Value of real-world DOAC data on atrial fibrillation treatment
Following the approval of direct oral anticoagulants (DOACs) a number of real-world studies were initiated to look at their impact on atrial fibrillation (AF) patients seen in daily practice. Unlike randomized … Continue Reading about Value of real-world DOAC data on atrial fibrillation treatment